MindWalk adds three executives from Pfizer, Novartis, Arbor

BOSTON - MindWalk Holdings Corp., a Bio-Native AI company, has appointed three senior executives to its development team as its pipeline nears preclinical efficacy studies, according to a press release. Zachary Maben, PhD, a former Principal Scientist at Arbor Biotechnologies and Pfizer, will serve as Director, Antigen Discovery & Protein Engineering.

Dr. Maben brings extensive experience in structure determination through X-ray crystallography and cryo-electron microscopy, having worked on twelve biologics project teams at Pfizer. Joanne Lim, PhD, who led immuno-oncology programs at Orum Therapeutics and Codiak Biosciences, will take on the role of Director, Preclinical Development.

Dr. Lim holds a PhD in Immunology and has over a decade of drug discovery experience. Shuji Sato, PhD, who has served as Vice President, Innovative Solutions at various biotech firms and Pfizer, will expand his responsibilities to include the company's pipeline prioritization decisions. Dr. Sato holds a PhD in Molecular Microbiology and has completed postdoctoral training at Harvard Medical School.

The new hires will all be based in Boston. MindWalk describes its platform as ReefIQ and LensAI, which integrate AI, data, and laboratory capabilities to advance its drug discovery efforts.